Anthony Quinn, EVP, CMO & Head of R&D at SYNAGEVA BIOPHARMA CORP (GEVA), sold 20,000 shares at $85.76 ($1.7M) on 2014-04-01, disclosed to the SEC on 2014-04-03.
Scheduled sale ($1.7M) by EVP, CMO & Head of R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $82.80 | 10,675 | $884K | 52.9% |
| 2 | $83.50 | 3,529 | $295K | 17.6% |
| 3 | $84.72 | 4,746 | $402K | 24.1% |
| 4 | $85.76 | 1,050 | $90K | 5.4% |
| Total | $83.53 avg | 20,000 | $1.7M | 100% |
| Filing → |
| GEVA | SELL | 2015-04-23 | $1.1M | — | Filing → |
| GEVA | SELL | 2015-04-17 | $1.1M | — | Filing → |
| GEVA | SELL | 2015-04-08 | $2.8M | — | Filing → |